Adrenergic beta-Antagonists

"Adrenergic beta-Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Descriptor ID	D000319
MeSH Number(s)	D27.505.519.625.050.200.200 D27.505.696.577.050.200.200
Concept/Terms	Adrenergic beta-Antagonists Adrenergic beta-Antagonists Adrenergic beta Antagonists beta-Antagonists, Adrenergic beta-Adrenergic Receptor Blockaders Blockaders, beta-Adrenergic Receptor Receptor Blockaders, beta-Adrenergic beta Adrenergic Receptor Blockaders beta-Adrenergic Blockers Blockers, beta-Adrenergic beta Adrenergic Blockers beta-Blockers, Adrenergic Adrenergic beta-Blockers beta Blockers, Adrenergic Adrenergic beta-Receptor Blockaders Adrenergic beta Receptor Blockaders Blockaders, Adrenergic beta-Receptor beta-Receptor Blockaders, Adrenergic beta-Adrenergic Blocking Agents Agents, beta-Adrenergic Blocking Blocking Agents, beta-Adrenergic beta Adrenergic Blocking Agents

Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-Antagonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Neurotransmitter Agents [D27.505.519.625]
Adrenergic Agents [D27.505.519.625.050]
Adrenergic Antagonists [D27.505.519.625.050.200]
Adrenergic beta-Antagonists [D27.505.519.625.050.200.200]
Physiological Effects of Drugs [D27.505.696]
Neurotransmitter Agents [D27.505.696.577]
Adrenergic Agents [D27.505.696.577.050]
Adrenergic Antagonists [D27.505.696.577.050.200]
Adrenergic beta-Antagonists [D27.505.696.577.050.200.200]

Below are MeSH descriptors whose meaning is related to "Adrenergic beta-Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Adrenergic beta-Antagonists" by people in this website by year, and whether "Adrenergic beta-Antagonists" was a major or minor topic of these publications.

Bar chart showing 43 publications over 19 distinct years, with a maximum of 4 publications in 2009 and 2018 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	0	1	1
2001	0	1	1
2002	0	3	3
2003	1	1	2
2004	1	0	1
2006	1	2	3
2007	1	1	2
2008	1	1	2
2009	1	3	4
2010	1	2	3
2011	0	2	2
2013	1	2	3
2015	0	3	3
2016	0	1	1
2017	1	0	1
2018	3	1	4
2019	1	3	4
2021	1	1	2
2022	0	1	1

Below are the most recent publications written about "Adrenergic beta-Antagonists" by people in Profiles.

Duran-Corbera A, Faria M, Ma Y, Prats E, Dias A, Catena J, Martinez KL, Raldua D, Llebaria A, Rovira X. A Photoswitchable Ligand Targeting the ?1 -Adrenoceptor Enables Light-Control of the Cardiac Rhythm. Angew Chem Int Ed Engl. 2022 07 25; 61(30):e202203449.

View in: PubMed
Rivera-Ortiz J, Pla-Tenorio J, Cruz ML, Colon K, Perez-Morales J, Rodriguez JA, Martinez-Sicari J, Noel RJ. Blockade of beta adrenergic receptors protects the blood brain barrier and reduces systemic pathology caused by HIV-1 Nef protein. PLoS One. 2021; 16(11):e0259446.

View in: PubMed
Giorgio CMR, Licata G, Briatico G, Babino G, Fulgione E, Gambardella A, Alfano R, Argenziano G. Comparison between propranolol 2% cream versus timolol 0.5% gel for the treatment of Kaposi sarcoma. Int J Dermatol. 2021 May; 60(5):631-633.

View in: PubMed
Gutman SJ, Costello BT, Papapostolou S, Iles L, Ja J, Hare JL, Ellims A, Marwick TH, Taylor AJ. Impact of sex, socio-economic status, and remoteness on therapy and survival in heart failure. ESC Heart Fail. 2019 10; 6(5):944-952.

View in: PubMed
Dahl L, Schultz A, McGibbon E, Brownlie J, Cook C, Elbarouni B, Katz A, Nguyen T, Sawatzky JA, Sinclaire M, Throndson K, Prior HJ, Fransoo R. Cardiovascular Medication Use and Long-Term Outcomes of First Nations and Non-First Nations Patients Following Diagnostic Angiography: A Retrospective Cohort Study. J Am Heart Assoc. 2019 08 20; 8(16):e012040.

View in: PubMed
Montoya A, Varela-Ramirez A, Dickerson E, Pasquier E, Torabi A, Aguilera R, Nahleh Z, Bryan B. The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer. Biomed J. 2019 06; 42(3):155-165.

View in: PubMed
Chia YMF, Teng TK, Tay WT, Anand I, MacDonald MR, Yap J, Chandramouli C, Richards AM, Tromp J, Ouwerkerk W, Ling LH, Lam CSP. Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus. Eur J Heart Fail. 2019 05; 21(5):685-688.

View in: PubMed
Arnold SV, Yap J, Lam CSP, Tang F, Tay WT, Teng THK, McGuire DK, Januzzi JL, Fonarow GC, Masoudi FA, Kosiborod M. Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. Diabetes Obes Metab. 2019 02; 21(2):261-266.

View in: PubMed
Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, Wander GS, Yap JJ, MacDonald MR, Xu CF, Chia YM, Shimizu W, Richards AM, Voors A, Lam CS. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018 09; 6(9):e1008-e1018.

View in: PubMed
Egbuche O, Ekechukwu I, Effoe V, Maduabum N, Millard HR, Maihemuti A, Cross JA, Adedinsewo D, Onwuanyi AE. Effect of ?-blocker Therapy on Hospital Readmission and Mortality in Heart Failure Patients With Concurrent Cocaine Use. J Cardiovasc Pharmacol Ther. 2018 11; 23(6):518-523.

View in: PubMed

People

Explore

Similar Concepts

Top Journals